Arbutus Biopharma
Update in progressABUS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company in the United States focused on infectious diseases. Its hepatitis B program includes Imdusiran, a subcutaneously delivered RNAi therapy (GalNAc) in Phase 2a that aims to suppress all HBV antigens including HBsAg, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b that may boost HBV-specific immunity. It licenses LNP tech from Alnylam. Formerly Tekmira, it was renamed in 2015 and is based in Warminster, PA.
Company score
- Sentiment
- -0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.52
- Governance
- -0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!